Spanish firm Clinica Baviera has advanced its European growth with the acquisition of Eyes Hospitals Group, marking its first foray into the UK market.
Advised by Cardiff’s Gambit Corporate Finance, this deal, potentially worth £20 million, signifies a strategic step in Clinica Baviera’s expansion plans.
Acquisition Details
The strategic acquisition of the Eye Hospitals Group by Spanish firm Clinica Baviera was advised by Cardiff-based Gambit Corporate Finance. This deal holds substantial financial significance with an initial consideration set at £10 million, potentially increasing to over £19 million, contingent upon future trading performance.
Clinica Baviera, listed on the Madrid Stock Market, recognised the value in this acquisition as part of their broader European growth strategy. With a market capitalisation surpassing £250 million, the firm has made a notable entry into the UK sector.
About Eye Hospitals Group
The Eye Hospitals Group operates primarily under the brands Optimax and Ultralase, offering a wide range of vision correction services, such as treatments for short-sightedness and presbyopia.
As a pioneer in the UK for laser eye surgery, Optimax stands as the group’s largest brand with 19 clinics nationwide. These clinics are strategically located in key cities, delivering comprehensive refractive surgery and ophthalmological treatments.
Strategic Implications for Clinica Baviera
This acquisition marks Clinica Baviera’s inaugural venture into the UK market and aligns with its strategy for organic and acquisition-led growth across Europe.
The Eye Hospitals Group, with a solid revenue stream of approximately £14.5 million, supports this strategy by providing an established operational framework.
The acquisition not only enhances Clinica Baviera’s presence but also leverages the respected reputation of the Optimax brand, known for pioneering laser eye surgery in the UK.
Role of Gambit Corporate Finance
Gambit Corporate Finance played a crucial role in negotiating the deal’s value and structure. Partners Frank Holmes and Sam Forman facilitated the transaction process, ensuring strategic alignment with Clinica Baviera’s objectives.
The firm’s expertise in cross-border transactions significantly contributed to accessing the UK ophthalmic market, setting a platform for potential geographic expansion.
Statements from Key Figures
Eduardo Baviera, Co-founder and CEO of Clinica Baviera, expressed enthusiasm for entering the UK market, acknowledging the significant role of Gambit Corporate Finance in executing the deal.
Frank Holmes of Gambit highlighted the strategic importance of this acquisition in enhancing Clinica Baviera’s market position, emphasising the firm’s capability in facilitating international business dealings.
Sam Forman noted that this acquisition underscores Gambit’s value in identifying and accessing targets, enhancing Clinica Baviera’s market leadership in Spain, Germany, and Italy.
Market Position and Future Prospects
Clinica Baviera’s strategic entry into the UK market is expected to bolster its competitive stance and expand its service offerings in ophthalmology.
With the acquisition of Eye Hospitals Group, the company is well-positioned to further its reputation as a leader in laser eye surgery across Europe.
The respected Optimax brand, under Clinica Baviera, is likely to contribute significantly to the company’s future growth and market expansion strategies.
Conclusion of the Transaction
The acquisition is set to provide a platform for Clinica Baviera to innovate and grow within the competitive UK healthcare market. It represents a key milestone in its expansion strategy.
With the support of Gambit Corporate Finance, Clinica Baviera aims to solidify its position and seize new opportunities across the UK and Europe.
The acquisition positions Clinica Baviera for significant growth in the UK ophthalmic sector.
Leveraging the established reputation of Optimax, the firm aims to fortify its market presence and explore further opportunities in Europe.
